|Bid||5.25 x 2200|
|Ask||5.27 x 3200|
|Day's Range||5.19 - 5.65|
|52 Week Range||1.56 - 7.25|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||5.36|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In a major coup for Ziopharm Oncology (ZIOP), the company has attracted the services of Drew Deniger, Ph.D., from the National Cancer Institute (NCI) to lead the company's program to genetically modify T-cells to express neoantigen-specific T-cell receptors (TCRs), effective July 29, 2019, explains John McCamant, editor of The Medical Technology Stock Letter.
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
The Boston-based company said it had a loss of 8 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
The big shareholder groups in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companie...
Ziopharm said the FDA granted Fast Track designation for its Ad-RTS-hIL-12 plus veledimex, which is being evaluated for the treatment of recurrent or progressive glioblastoma multiforme, or rGBM in adults. The Fast Track designation facilitates the development and expediting of the review of drugs to treat serious conditions.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Laurence James Cooper has been the CEORead More...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
Ziopharm Oncology (ZIOP) needs investors to pay close attention to the stock based on moves in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
Ziopharm (ZIOP) delivered earnings and revenue surprises of -18.18% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like ZIOPHARM Oncology Inc (NASDAQ:ZIOP), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
Ziopharm (ZIOP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.